{"id":918803,"date":"2025-12-11T10:01:40","date_gmt":"2025-12-11T15:01:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/"},"modified":"2025-12-11T10:01:40","modified_gmt":"2025-12-11T15:01:40","slug":"profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/","title":{"rendered":"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>Study conducted at US sites evaluates Lumee<\/i><br \/>\n        <sup><br \/>\n          <i>TM<\/i><br \/>\n        <\/sup><br \/>\n        <i>in peripheral artery disease (PAD) patients<\/i>\n      <\/p>\n<p align=\"justify\">BERKELEY, Calif, Dec.  11, 2025  (GLOBE NEWSWIRE) &#8212;  Profusa, Inc. (\u201cProfusa\u201d or the \u201cCompany\u201d) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual\u2019s biochemistry, announces the acceptance of their abstract at the upcoming Leipzig Interventional Course (LINC) 2026, being held January 27-30, 2026, in Leipzig, Germany. The presentation will discuss additional insights into tissue oxygen monitoring of PAD patients from Profusa\u2019s US-based pilot clinical study on Wednesday, January 28<sup>th<\/sup>, 2026, 9:45am CET at the Trade Fair Leipzig, Hall 2.<\/p>\n<p align=\"justify\">\u201cOur proprietary Lumee oxygen tissue monitoring technology enables continuous, real-time measurement of tissue oxygen directly within the body, intended for use both in the clinic and at home,\u201d said Ben Hwang, Ph.D., Profusa\u2019s Chairman and CEO. \u201cWith positive feedback from our U.S.-based clinical study evaluating our pioneering Lumee technology with tcpO<sub>2<\/sub>, we look forward to sharing additional clinical results and continued discussion with providers and researchers at this preeminent European conference.\u201d<\/p>\n<p align=\"justify\">\n        <b>About Profusa<\/b><br \/>\n        <br \/>Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.<\/p>\n<p align=\"justify\">\u201cLUMEE\u201d, \u201cPROFUSA\u201d and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.<\/p>\n<p>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aNFpCyXnmEakIxmacgEbFzqbBSftHjt6wuz8fB1AsvNjfX5mwKc4C27fyGqBXBj_5ZOY649P-Qu3zt-h9b4lDVfTpcYrX-FtDOO02MX-Cbc=\" rel=\"nofollow\" target=\"_blank\">https:\/\/profusa.com.<\/a><\/p>\n<p align=\"justify\">\n        <b>Special Note Regarding Forward-Looking Statements<\/b><br \/>\n        <br \/>Certain statements in this press release (this \u201cPress Release\u201d) may be considered \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cforecast,\u201d \u201cfuture,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpropose,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201cwill,\u201d or \u201cwould\u201d or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy\/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.<\/p>\n<p>\n        <b>Contacts<\/b><br \/>\n        <br \/>\n        <b>Investor and Media Contacts<\/b><br \/>\n        <br \/>email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-N22jroZN1VEp1PoewBjcDqwjW37eGBEiWT2lfiLWPPE1MHhnfqZ1I330ITDx1hViIx_Hd01XJzxm1o5p6o2tbrpiWjPKrWrJhWgs8Nv2Ak=\" rel=\"nofollow\" target=\"_blank\">info@coreir.com<\/a><br \/>phone: 1 (212) 655-0924<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWI1M2NhYzAtOTE0Yy00NGE2LWJkOTAtMmIxMjdjYWE1MTZmLTUwMDA5ODI1NC0yMDI1LTEyLTExLWVu\/tiny\/Profusa-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Study conducted at US sites evaluates Lumee TM in peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) &#8212; Profusa, Inc. (\u201cProfusa\u201d or the \u201cCompany\u201d) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual\u2019s biochemistry, announces the acceptance of their abstract at the upcoming Leipzig Interventional Course (LINC) 2026, being held January 27-30, 2026, in Leipzig, Germany. The presentation will discuss additional insights into tissue oxygen monitoring of PAD patients from Profusa\u2019s US-based pilot clinical study on Wednesday, January 28th, 2026, 9:45am CET at the Trade Fair Leipzig, Hall 2. \u201cOur proprietary Lumee oxygen tissue monitoring technology enables continuous, real-time measurement of tissue oxygen directly within &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-918803","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Study conducted at US sites evaluates Lumee TM in peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) &#8212; Profusa, Inc. (\u201cProfusa\u201d or the \u201cCompany\u201d) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual\u2019s biochemistry, announces the acceptance of their abstract at the upcoming Leipzig Interventional Course (LINC) 2026, being held January 27-30, 2026, in Leipzig, Germany. The presentation will discuss additional insights into tissue oxygen monitoring of PAD patients from Profusa\u2019s US-based pilot clinical study on Wednesday, January 28th, 2026, 9:45am CET at the Trade Fair Leipzig, Hall 2. \u201cOur proprietary Lumee oxygen tissue monitoring technology enables continuous, real-time measurement of tissue oxygen directly within &hellip; Continue reading &quot;Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-11T15:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026\",\"datePublished\":\"2025-12-11T15:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/\"},\"wordCount\":578,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/\",\"name\":\"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA==\",\"datePublished\":\"2025-12-11T15:01:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/","og_locale":"en_US","og_type":"article","og_title":"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - Market Newsdesk","og_description":"Study conducted at US sites evaluates Lumee TM in peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) &#8212; Profusa, Inc. (\u201cProfusa\u201d or the \u201cCompany\u201d) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual\u2019s biochemistry, announces the acceptance of their abstract at the upcoming Leipzig Interventional Course (LINC) 2026, being held January 27-30, 2026, in Leipzig, Germany. The presentation will discuss additional insights into tissue oxygen monitoring of PAD patients from Profusa\u2019s US-based pilot clinical study on Wednesday, January 28th, 2026, 9:45am CET at the Trade Fair Leipzig, Hall 2. \u201cOur proprietary Lumee oxygen tissue monitoring technology enables continuous, real-time measurement of tissue oxygen directly within &hellip; Continue reading \"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-11T15:01:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026","datePublished":"2025-12-11T15:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/"},"wordCount":578,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/","name":"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA==","datePublished":"2025-12-11T15:01:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDQyOSM3MzE2NjQ0IzUwMDA5ODI1NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/profusa-to-present-us-study-clinical-data-at-leipzig-interventional-course-linc-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/918803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=918803"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/918803\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=918803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=918803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=918803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}